drug
budesonide DR
Marketedupdated 3mo agoby Calliditas Therapeutics AB
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval8 co-mentions · 4 sources
- drugbudesonide ER6 co-mentions · 6 sources
- drugBUDESONIDE6 co-mentions · 6 sources
- drugPulmicort6 co-mentions · 6 sources
- drugPulmicort Turbohaler6 co-mentions · 6 sources
- tagSmall Molecule4 co-mentions · 4 sources
- tagRecall2 co-mentions · 2 sources
- companyAstraZeneca Pharmaceuticals LP1 co-mentions · 1 sources
all catalysts(4)
Trials studying budesonide DR
- phase3A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
- phase3A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
- phase3Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
- phase4Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
- phase2Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
- phase1A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
- —Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- phase4A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 9, 2026
80 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (35)
- Jan 23, 2043method-of-use (U-3810)US 11896719
- Jan 23, 2043method-of-use (U-4086)US 12171882
- Jan 23, 2043formulationUS 12171883
- Jan 23, 2043formulationUS 12311057
- Jan 10, 2039formulationUS 11260064
- Jan 10, 2039method-of-use (U-3820)US 11564934
- Oct 5, 2038formulationUS 11331442
- Oct 5, 2038formulationUS 11833292
- Sep 9, 2036method-of-use (U-2554)US 10172802
- Sep 9, 2036method-of-use (U-2554)US 10172802
- Sep 9, 2036formulationUS 9707182
- Sep 9, 2036formulationUS 9707182
- Sep 7, 2031formulationUS 10307375
- Sep 7, 2031formulationUS 10660858
- Sep 7, 2031formulationUS 8895064
- Sep 7, 2031formulationUS 9132093
- Sep 7, 2031formulationUS 9192581
- Mar 17, 2031method-of-use (U-2889)US 88152584.6y
- May 28, 2030formulationUS 107167533.8y
- May 28, 2030method-of-use (U-2889)US 83242663.8y
- May 28, 2030method-of-use (U-2889)US 87038063.8y
- May 28, 2030formulationUS 88087133.8y
- May 28, 2030method-of-use (U-2889)US 94150093.8y
- May 28, 2030formulationUS 94631613.8y
- Aug 3, 2029method-of-use (U-3820)US 83241923.0y
- Aug 1, 2029formulationUS 90503682.9y
- May 7, 2029formulationUS 84919322.7y
- Nov 22, 2028formulationUS 102930522.3y
- Nov 12, 2028method-of-use (U-3820)US 113578592.2y
- Nov 9, 2026formulationUS 1119782280d
- Nov 9, 2026formulationUS 1141329680d
- Nov 9, 2026method-of-use (U-3820)US 849725880d
- Nov 9, 2026formulationUS 867954580d
- Nov 9, 2026method-of-use (U-3820)US 897524380d
- Nov 9, 2026method-of-use (U-3820)US 911986380d
FDA exclusivities (4)
- Feb 9, 2031ODE-466Orphan Drug (7y)4.5y
- Dec 20, 2030ODE-464Orphan Drug (7y)4.3y
- Dec 15, 2028ODE-389Orphan Drug (7y)2.3y
- Feb 9, 2027NPNP172d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that